Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39729 SOTERA HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 47-3531161 (State or other jurisdiction of incorporation ...

Nelson Labs: Q4 revenue increased 2.3% to $55 million (nearly flat constant currency). Pricing and core lab testing growth were partially offset by lower expert advisory services revenue. Segment income rose 1.9% to $18 million.Nordion: Q4 revenue declined 12.3% to $50 million due to harvest-schedule timing that drove 15% unfavorable volume and mix, partially offset by 2.4% favorable pricing. Segment income fell 18.9% to $29 million, with margin down 466 basis points to 57.5%.Sterigenics: Q4 revenue grew 10 ...

Sotera Health Company (NasdaqGS:SHC) Q4 2025 Earnings call February 24, 2026 09:00 AM ET Company ParticipantsDavid Windley - Managing Director and Founding Member of Healthcare Equity Research TeamJason Peterson - VP of Investor Relations and TreasuryJonathan M. Lyons - CFOMichael Petras - Chairman and CEOSam Eiber - Equity Research AssociateConference Call ParticipantsBrett Fishman - VP and Senior Equity Research AnalystCasey Woodring - VP and Senior Equity Research AnalystChristine Rains - Healthcare Equi ...

Financial Data and Key Metrics Changes - Total company revenue increased by 5.7% to $1.164 billion in 2025, or 5.2% growth on a constant currency basis compared to 2024 [5][15] - Adjusted EBITDA rose by 8.2% to $593.8 million, or 7.8% on a constant currency basis, with margins expanding to 51%, an increase of 118 basis points [5][15] - Adjusted EPS for the year was $0.86, an increase of $0.16 versus 2024, driven by operational growth and a lower tax rate [16] Business Line Data and Key Metrics Changes - Sterigenics revenue improved by 10.6% to $198 million, or 8% on a constant currency basis, driven by favorable pricing and volume [12] - Nordion's revenue decreased by 12.3% to $50 million due to unfavorable volume and mix from Cobalt-60 harvest timing [13] - Nelson Labs revenue increased by 2.3% to $55 million, with favorable pricing and core lab testing growth partially offset by lower advisory services revenue [14] Market Data and Key Metrics Changes - Customer satisfaction exceeded 80%, indicating strong service delivery [6] - Revenue from XBU customers expanded by 9% year-over-year, reflecting successful cross-selling initiatives [6][50] Company Strategy and Development Direction - The company aims to execute its 2025-2027 long-range plan, focusing on operational excellence, disciplined capital deployment, and enhancing free cash flow [8][21] - The construction of a new X-ray facility is planned to open in 2026, which is part of a strategic investment to expand service offerings [6][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive long-term growth and shareholder value, emphasizing strong cash flow generation and customer relationships [21][105] - The company expects total revenue for 2026 to be in the range of $1.233 billion to $1.251 billion, representing 5%-6.5% constant currency growth [9][18] Other Important Information - The company reduced borrowing costs by 75 basis points on its $1.4 billion term loan and paid down $86 million of debt, resulting in annual interest savings of $13 million [7] - The company has approximately $940 million of available liquidity as of December 31, 2025 [16] Q&A Session Summary Question: Guidance and EBITDA margins - Management indicated that the expected EBITDA margin expansion is primarily due to normal operating leverage without any unusual dynamics [23][24] Question: Sterigenics client insourcing - Management noted that while one client is transitioning back to outsourcing, significant shifts in the market are not yet observed due to extended compliance periods [25][26] Question: 2026 outlook for Sterigenics - Management expects mid to high single-digit constant currency revenue growth for Sterigenics in 2026, with a soft start anticipated in Q1 [18][32] Question: Nelson Labs margins - Management expects Nelson Labs to maintain margins in the low to mid 30% range, with Q1 typically being the softest quarter [34][35] Question: Nordion segment headwinds - Management clarified that Nordion's challenges were due to Cobalt-60 harvest timing rather than demand issues [84][85] Question: Competitive positioning in Sterigenics - Management believes Sterigenics is well-positioned despite the extended compliance period, with strong customer satisfaction scores [68][69] Question: Impact of onshoring - Management has not seen significant movement towards onshoring but is prepared for potential shifts in the market [87] Question: Volume and mix visibility - Management indicated that volume and mix are key factors that could drive performance towards the higher end of guidance [91][92]

Sotera Health Company (NasdaqGS:SHC) Q4 2025 Earnings call February 24, 2026 09:00 AM ET Speaker9Please note this event is being recorded. I would now like to turn the conference over to Vice President of Investor Relations, Jason Peterson. Jason, please go ahead.Speaker5Good morning. Thank you. Welcome to Sotera Health's fourth quarter and full year 2025 earnings call. Today's press release and supplemental slides are available on the investor section of our website at soterahealth.com. This webcast is bei ...

Sotera Health Company (SHC) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +7.22%. A quarter ago, it was expected that this company would post earnings of $0.22 per share when it actually produced earnings of $0.26, delivering a surprise of +18.18%.Over the last four quarters, the co ...

Cautionary Note Regarding Forward-Looking Statements and Non-GAAP Financial Measures Unless expressly indicated or the context requires otherwise, the terms "Sotera Health," "Company," "we," "us," and "our" in this presentation refer to Sotera Health Company, a Delaware corporation, and, where appropriate, its subsidiaries on a consolidated basis. This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are ...

2025 net revenues increased 5.7% to $1.164 billion, compared to 2024, or 5.2% on a constant currency basis2025 net income increased to $78 million or $0.27 per diluted share, compared to net income of $44 million, or $0.16 per diluted share, in 20242025 Adjusted EBITDA(1) increased 8.2% to $594 million, compared to 2024, or 7.8% on a constant currency basis2025 Adjusted EPS(1) of $0.86, an increase of $0.16 per diluted share, compared to 2024Full-year 2026 outlook: net revenues growth of 5.0% to 6.5% and Ad ...

Core Viewpoint - Sotera Health Company is set to release its financial results for Q4 and the full year of 2025 on February 24, 2026, before market opening, followed by a conference call to discuss the results and operational highlights [1]. Group 1 - The financial results will cover the period ending December 31, 2025 [1]. - A conference call is scheduled for 9:00 a.m. Eastern Time on the same day to discuss the results [1]. - A live webcast of the conference call will be available on the company's Investor Relations website, with a replay accessible later that day [2]. Group 2 - Sotera Health is recognized as a leading global provider of sterilization solutions, lab testing, and advisory services for the healthcare industry [4]. - The company operates through three business segments: Sterigenics, Nordion, and Nelson Labs [4]. - Sotera Health is dedicated to its mission of safeguarding global health [4].

Core Viewpoint - Sotera Health Company has appointed Richard G. Kyle as a new independent director to its Board of Directors, enhancing its leadership team with his extensive experience in operations and governance [1][2][3]. Group 1: Appointment Details - Richard G. Kyle will serve on the Leadership Development and Compensation Committee and the Nominating and Corporate Governance Committee [1]. - His previous role was as President and CEO of The Timken Company, where he led financial transformation and strategic diversification [2]. - Kyle's selection is based on his experience in leading global operations and strong financial acumen [2][3]. Group 2: Leadership Insights - Michael B. Petras, Jr., Chairman and CEO of Sotera Health, expressed excitement about Kyle's appointment, highlighting his leadership experience as a public company CEO [3]. - Kyle continues to serve on Timken's Board and has been on the Board of Sonoco Products Company since 2015, where he holds multiple committee roles [3]. Group 3: Company Overview - Sotera Health is a global provider of sterilization solutions, lab testing, and advisory services for the healthcare industry [4]. - The company operates through three business segments: Sterigenics, Nordion, and Nelson Labs, with a commitment to safeguarding global health [4].